PharMerica adopts poison pill to prevent takeover

Friday, August 26, 2011 01:25 PM

U.S. pharmacy services provider PharMerica adopted a poison pill to prevent hostile takeovers, two days after Omnicare went public with its bid to acquire the company for $441 million, according to Reuters.

The stockholder rights plan -- commonly referred to as a poison pill -- gives the company the right to issue new shares if a shareholder acquires a 15% stake or more, thus diluting the holdings of the shareholder.

PharMerica rejected Omnicare's bid saying it undervalued the company and could run into regulatory hurdles.

Deutsche Bank Securities is acting as financial adviser for PharMerica.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs